Peregrine Pharmaceuticals to Present at Rodman & Renshaw Annual Healthcare Conference
- Presentation to be Webcast Live and Archived on the Company's Website -
TUSTIN, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced that it will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference at the New York Palace Hotel in New York City on Tuesday, November 8, 2005 at 8:00am EST in the Kennedy II Room.
Peregrine CEO and president Steven King will provide a review of recent corporate developments, including progress in the company's clinical programs for its cancer drugs Cotara® and Tarvacin™ Anti-Cancer, as well as encouraging developments in its Tarvacin™ Anti-Viral program, including its ongoing clinical trial for hepatitis C infection and preclinical programs in influenza and other life-threatening viral infections.
Mr. King's presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.peregrineinc.com. A replay will be available on the Peregrine website approximately three hours after the presentation and will be archived for approximately 90 days.
About Peregrine
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and viral diseases. The company is pursuing three separate clinical trials in cancer and anti-viral indications with its lead product candidates Tarvacin™ and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Investors
Barbara Lindheim
GendeLLindheim BioCom Partners
(800) 987-8256
ir@peregrineinc.com
SOURCE Peregrine Pharmaceuticals, Inc.